ICAM1 and hepatocellular carcinoma: Although expression levels of ICAM-1 did not differ significantly from the control group in that study, hepatic ICAM-1+ CTCs from HCC patients show high tumorigenic activity in vivo and their frequency is an independent risk factor of portal vein tumor thrombus and ascites [97].